AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26568032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tosedostat (120 mg on days 1-21 or 180 mg continuously) with cytarabine (1 g/m2/d) or decitabine (20 mg/m2/d) every 35 days
Number of subjects: 34
Study 26568032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tosedostat with cytarabine or decitabine
Number of subjects: 34
Study 24286967 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline drinking to cope with negative affect
Number of subjects: 254
Study 23079311 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof Restor SN6AD3 apodized multifocal IOL
Number of subjects: 0
Study 23079311 — intervention group
Group type: EXPERIMENTAL
Intervention: AT LISA 366D diffractive multifocal IOL
Number of subjects: 0
Study 23079311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis ZMA00 diffractive multifocal IOL
Number of subjects: 0
Study 23079311 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezoom refractive multifocal IOL
Number of subjects: 0
Study 23079311 — intervention group
Group type: EXPERIMENTAL
Intervention: Acri.Smart 48S monofocal IOL
Number of subjects: 0
Study 23079311 — intervention group
Group type: COMPARATOR
Intervention: Control group (monofocal and refractive multifocal IOLs)
Number of subjects: 0
Study 19578230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human albumin 20% (1 g/kg) one hour before exchange
Number of subjects: 50
Study 19578230 — intervention group
Group type: COMPARATOR
Intervention: Control group underwent a blood exchange
Number of subjects: 50
Study 18725147 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based, stage-tailored Internet program, F&V Express Bites
Number of subjects: 160
Study 18725147 — intervention group
Group type: COMPARATOR
Intervention: Nontailored messages
Number of subjects: 160
Study 16078036 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori (HP) eradication therapy
Number of subjects: 17
Study 16078036 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) monotherapy
Number of subjects: 17
Study 12494080 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0
Study 10367046 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intermittent MFP (3 months on, 1 month off) with 1000 mg calcium/day (average daily fluoride ion dose of 11.2 mg)
Number of subjects: 134
Study 10367046 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous MFP with 1000 mg calcium/day (20 mg fluoride ions per day)
Number of subjects: 134
Study 10367046 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone (1000 mg/day)
Number of subjects: 134
Study 7499031 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-MAC sevoflurane, isoflurane, or enflurane
Number of subjects: 31
Study 7499031 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-MAC sevoflurane, isoflurane, or enflurane
Number of subjects: 31
Study 7499031 — intervention group
Group type: COMPARATOR
Intervention: Control (medium alone)
Number of subjects: 31
Study 7499031 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanesthetic (air exposure)
Number of subjects: 31
Study 7499031 — intervention group
Group type: EXPERIMENTAL
Intervention: All anesthetics (1.5-MAC and 2.5-MAC)
Number of subjects: 31
Study 2019084 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection of subjects with DMFT greater than 4 and at least three permanent second molars erupted
Number of subjects: 3005
Study 6780232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (continuous infusion over 48 hours initiated within 8 hours after onset of symptoms)
Number of subjects: 31
Study 6780232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (late intervention, therapy begun more than 8 hours after onset of symptoms)
Number of subjects: 31
Study 6780232 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitroglycerin treatment)
Number of subjects: 31
Study 31619359 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical natamycin 5% alone
Number of subjects: 0
Study 31619359 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical natamycin 5% plus CXL
Number of subjects: 0
Study 31619359 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amphotericin B 0.15% alone
Number of subjects: 0
Study 31619359 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amphotericin 0.15% plus CXL
Number of subjects: 0
Study 31619359 — intervention group
Group type: EXPERIMENTAL
Intervention: CXL regardless of medication
Number of subjects: 0
Study 31248663 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Number of subjects: 0
Study 31248663 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28295141 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 196
Study 28295141 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 196
Study 28295141 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 196
Study 28295141 — intervention group
Group type: COMPARATOR
Intervention: All AChEIs
Number of subjects: 196
Study 26920594 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 388
Study 26920594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully adherent patients
Number of subjects: 388
Study 26920594 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially adherent patients
Number of subjects: 388
Study 26920594 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent patients
Number of subjects: 388
Study 25503627 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace social capital intervention (team building courses, public services, psychological consultation, outdoor training)
Number of subjects: 447
Study 25503627 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 447
Study 23111090 — intervention group
Group type: EXPERIMENTAL
Intervention: Single port/incision laparoscopic surgery
Number of subjects: 0
Study 23111090 — intervention group
Group type: COMPARATOR
Intervention: Standard three-port laparoscopic surgery
Number of subjects: 0
Study 20708576 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Number of subjects: 0
Study 20708576 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine
Number of subjects: 0
Study 17068160 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance training (RMT)
Number of subjects: 21
Study 17068160 — intervention group
Group type: COMPARATOR
Intervention: Sham training (CON)
Number of subjects: 21
Study 16280443 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (50,000 IU for ages 2‐12 months; 100,000 IU for ages >12‐59 months)
Number of subjects: 287
Study 16280443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 12198018 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (714 mg/d for 12 months)
Number of subjects: 160
Study 12198018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 10200128 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2 g/kg dose of IVGG
Number of subjects: 203
Study 10200128 — intervention group
Group type: COMPARATOR
Intervention: Non-IVGG treatment
Number of subjects: 203
Study 10200128 — intervention group
Group type: COMPARATOR
Intervention: 400 mg/kg per day for 5 consecutive days of IVGG
Number of subjects: 203
Study 1456570 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 50 mg at 1500 h
Number of subjects: 7
Study 1456570 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 50 mg at 0800 h
Number of subjects: 7
Study 1456570 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 50 mg at 2000 h
Number of subjects: 7
Study 1456570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3969541 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metolazone
Number of subjects: 35
Study 3969541 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg furosemide
Number of subjects: 35
Study 3969541 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pindolol
Number of subjects: 35
Study 3969541 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg hydralazine
Number of subjects: 35
Study 3969541 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic monotherapy (metolazone or furosemide)
Number of subjects: 35
Study 3969541 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of three different antihypertensive agents
Number of subjects: 35
Study 3969541 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care approach
Number of subjects: 35
Study 31114137 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bacillus subtilis and Enterococcus faecium) with esomeprazole 20 mg b.i.d. for 8 weeks
Number of subjects: 134
Study 31114137 — intervention group
Group type: COMPARATOR
Intervention: Placebo with esomeprazole 20 mg b.i.d. for 8 weeks
Number of subjects: 134
Study 30129913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive triage
Number of subjects: 0
Study 30129913 — intervention group
Group type: COMPARATOR
Intervention: START triage
Number of subjects: 0
Study 30129913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive triage and START
Number of subjects: 0
Study 26299677 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline heart rate in sinus rhythm
Number of subjects: 5164
Study 26299677 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline heart rate >114 bpm in atrial fibrillation
Number of subjects: 5164
Study 26299677 — intervention group
Group type: COMPARATOR
Intervention: Baseline heart rate 90-114 bpm in atrial fibrillation
Number of subjects: 5164
Study 26206311 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program combined with conventional cardiac rehabilitation (n=70)
Number of subjects: 140
Study 26206311 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation alone (n=70)
Number of subjects: 140
Study 23812240 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 440
Study 23812240 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation
Number of subjects: 440
Study 21099198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride (EC) spray
Number of subjects: 51
Study 21099198 — intervention group
Group type: COMPARATOR
Intervention: Saline spray (placebo)
Number of subjects: 51
Study 18199135 — intervention group
Group type: EXPERIMENTAL
Intervention: Group care (83 patients, 27 Type 1 and 56 Type 2)
Number of subjects: 162
Study 18199135 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (79 patients, 28 Type 1 and 51 Type 2)
Number of subjects: 162
Study 18199135 — intervention group
Group type: EXPERIMENTAL
Intervention: Group care (Type 1 diabetes)
Number of subjects: 162
Study 18199135 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (Type 1 diabetes)
Number of subjects: 162
Study 18199135 — intervention group
Group type: EXPERIMENTAL
Intervention: Group care (Type 2 diabetes)
Number of subjects: 162
Study 18199135 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (Type 2 diabetes)
Number of subjects: 162
Study 17012873 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax-DEN2 (high dose, 5 log PFU)
Number of subjects: 56
Study 17012873 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax-DEN2 (low dose, 3 log PFU)
Number of subjects: 56
Study 17012873 — intervention group
Group type: COMPARATOR
Intervention: YF-VAX
Number of subjects: 56
Study 17012873 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax-DEN2 (high dose) in YF immune subjects
Number of subjects: 56
Study 17012873 — intervention group
Group type: COMPARATOR
Intervention: ChimeriVax-DEN2 and YF-VAX
Number of subjects: 56
Study 17012873 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax-DEN2 in YF immune subjects
Number of subjects: 56
Study 14617474 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa (buserelin acetate, 900 microg/day for 10-12 weeks followed by 4 weeks postoperative treatment)
Number of subjects: 15
Study 14617474 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 15
Study 11063436 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L/d of paper-filtered coffee brewed with 70 g regular ground beans
Number of subjects: 26
Study 11063436 — intervention group
Group type: COMPARATOR
Intervention: No coffee
Number of subjects: 26
Study 9160935 — intervention group
Group type: EXPERIMENTAL
Intervention: Nailing with reaming
Number of subjects: 135
Study 9160935 — intervention group
Group type: COMPARATOR
Intervention: Nailing without reaming
Number of subjects: 135
Study 8428870 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate alone
Number of subjects: 96
Study 8428870 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate in combination with behavioral parent training plus child self-control instruction
Number of subjects: 96
Study 8428870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 96
Study 3619741 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of intravenous metoclopramide hydrochloride
Number of subjects: 100
Study 3619741 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 100
Study 30359821 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype content assessment for Black and poor children
Number of subjects: 93
Study 30359821 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype strength assessment for constructs related to race-abuse and social class-abuse
Number of subjects: 93
Study 27219616 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (Metoprolol, 37±13.5 mg, n=48)
Number of subjects: 100
Study 27219616 — intervention group
Group type: COMPARATOR
Intervention: No beta-blockers (n=52)
Number of subjects: 100
Study 24593273 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term administration of itraconazole (ITCZ) - 400 mg/day for 2 days followed by 200 mg/day until day +90 post transplantation.
Number of subjects: 128
Study 24593273 — intervention group
Group type: COMPARATOR
Intervention: Short-term administration of itraconazole (ITCZ) - 400 mg/day for 2 days followed by 200 mg/day until day +30 post transplantation.
Number of subjects: 128
Study 24593273 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term administration of itraconazole (ITCZ) from day +30 to day +90.
Number of subjects: 128
Study 24593273 — intervention group
Group type: COMPARATOR
Intervention: Short-term administration of itraconazole (ITCZ) from day +30 to day +90.
Number of subjects: 128
Study 24593273 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term administration of itraconazole (ITCZ) - drug-related adverse events.
Number of subjects: 128
Study 24593273 — intervention group
Group type: COMPARATOR
Intervention: Short-term administration of itraconazole (ITCZ) - drug-related adverse events.
Number of subjects: 128
Study 22536073 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (2.4 g omega-3, 1800 mg eicosapentaenoic acid + 600 mg docosahexaenoic acid)
Number of subjects: 63
Study 22536073 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 63
Study 22536073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 20688775 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (30 mg/kg over 10 minutes in normal saline)
Number of subjects: 50
Study 20688775 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (5 ml over 10 minutes)
Number of subjects: 50
Study 18454609 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion (CSCI) of opioid for 48 hours
Number of subjects: 11
Study 18454609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent subcutaneous injections (ISCI) of opioid for 48 hours
Number of subjects: 11
Study 15720906 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive carpal tunnel decompression
Number of subjects: 194
Study 15720906 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 194
Study 12578516 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Telemanagement (NTM)
Number of subjects: 216
Study 12578516 — intervention group
Group type: COMPARATOR
Intervention: Nurse Telemanagement (NTM) and Home Nurse Visit (HNV)
Number of subjects: 216
Study 10563072 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4-8 mg
Number of subjects: 32
Study 10563072 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10-20 mg
Number of subjects: 32
Study 10563072 — intervention group
Group type: COMPARATOR
Intervention: Perindopril and Enalapril
Number of subjects: 32
Study 8690820 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus epoprostenol
Number of subjects: 23
Study 8690820 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 23
Study 1737346 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN gamma and rIFN alpha
Number of subjects: 28
Study 6503242 — intervention group
Group type: COMPARATOR
Intervention: Adult talk (5 min)
Number of subjects: 3
Study 6503242 — intervention group
Group type: COMPARATOR
Intervention: Mixed condition (alternating 30-s periods of silence and talk)
Number of subjects: 3
Study 6503242 — intervention group
Group type: COMPARATOR
Intervention: Modified talk (question or comment every 10 s)
Number of subjects: 3
Study 30700482 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised telehealth intervention (one telephone call per fortnight and 2-8 tailored text messages for 3 months, followed by 4-12 tailored text messages for 3 months without telephone calls)
Number of subjects: 80
Study 30700482 — intervention group
Group type: COMPARATOR
Intervention: Usual care followed by non-tailored education-only text messages for 3 months
Number of subjects: 80
Study 30132926 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted NOAC therapy
Number of subjects: 101
Study 30132926 — intervention group
Group type: COMPARATOR
Intervention: Interrupted NOAC therapy
Number of subjects: 101
Study 30132926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study 26770041 — intervention group
Group type: EXPERIMENTAL
Intervention: Avaxim™
Number of subjects: 0
Study 26770041 — intervention group
Group type: EXPERIMENTAL
Intervention: Epaxal®
Number of subjects: 0
Study 26770041 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix®
Number of subjects: 0
Study 25142484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground-based walking training (supervised, 2-3 times a week for 8-10 weeks)
Number of subjects: 130
Study 25142484 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 130
Study 22357633 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Task Practice (FTP)
Number of subjects: 14
Study 22357633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Resistance Training (POWER)
Number of subjects: 14
Study 22357633 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment order B (POWER followed by FTP)
Number of subjects: 14
Study 19071128 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (1500 mg)
Number of subjects: 25
Study 19071128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17237450 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants informed of morbidity costs
Number of subjects: 181
Study 17237450 — intervention group
Group type: COMPARATOR
Intervention: Participants uninformed of morbidity costs
Number of subjects: 181
Study 17237450 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness severity levels
Number of subjects: 181
Study 17237450 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between illness severity and prior knowledge
Number of subjects: 181
Study 16190818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy in patients with rapid noncomplicated healing of leg fractures
Number of subjects: 2
Study 16190818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy in patients with protracted healing and undergoing surgical reconstructions
Number of subjects: 2
Study 12493085 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breakfast with predominantly saturated fatty acids (SFA)
Number of subjects: 10
Study 12493085 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breakfast with n-6 polyunsaturated fatty acids (PUFA)
Number of subjects: 10
Study 12493085 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breakfast with long-chain n-3 PUFA
Number of subjects: 10
Study 12493085 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breakfast with monounsaturated fatty acids (MUFA)
Number of subjects: 10
Study 12493085 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate lunch (5.7 g fat)
Number of subjects: 10
Study 9609272 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage postpartum perineal repair leaving the skin unsutured
Number of subjects: 1780
Study 9609272 — intervention group
Group type: COMPARATOR
Intervention: Three-stage repair including skin closure with interrupted or subcuticular sutures
Number of subjects: 1780
Study 7639167 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the TIMI 5 trial
Number of subjects: 0
Study 7639167 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex trials designed to improve reperfusion therapy
Number of subjects: 0
Study 2093803 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath‐Taker peak flow meter
Number of subjects: 30
Study 2093803 — intervention group
Group type: EXPERIMENTAL
Intervention: mini‐Wright peak flow meter
Number of subjects: 30
Study 2093803 — intervention group
Group type: EXPERIMENTAL
Intervention: Wright peak flow meter
Number of subjects: 30
Study 2093803 — intervention group
Group type: COMPARATOR
Intervention: pneumotachograph system
Number of subjects: 30
Study 934747 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary pediatric care
Number of subjects: 0
Study 934747 — intervention group
Group type: COMPARATOR
Intervention: Episodic care (Control)
Number of subjects: 0
Study 29373698 — intervention group
Group type: EXPERIMENTAL
Intervention: Snus alone
Number of subjects: 649
Study 29373698 — intervention group
Group type: EXPERIMENTAL
Intervention: Snus plus information
Number of subjects: 649
Study 29373698 — intervention group
Group type: COMPARATOR
Intervention: Nicotine lozenge
Number of subjects: 649